Single-Dose Fosaprepitant Effective in Preventing CINV with Moderately Emetogenic Chemotherapy
July 1st 2015A single intravenous dose of fosaprepitant dimeglumine was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
More Sensitive Stress-Management Tools Needed for Latina Women With Breast Cancer
June 26th 2015A study looking at the care experiences and possible stressors for Latina women undergoing chemotherapy to treat their breast cancer has found that this patient population feels particular stress related to their family and other interpersonal relationships.
Prostate Cancer Foundation Steps Into the Ring to Knock Out Prostate Cancer for Good
June 25th 2015The Prostate Cancer Foundation is throwing a one-two punch to knock out prostate cancer for good with the recent production of a public service announcement featuring boxing legend and five-time heavyweight champion of the world Evander Holyfield.
Relieving Nausea With Olanzapine in Patients Treated for Head and Neck Cancer
June 18th 2015Nausea and vomiting associated with anticancer therapies continue to be among patients' most troubling symptoms. Findings of a clinical trial found that olanzapine demonstrated comparative benefits in relieving these symptoms.
More Women Are Choosing Breast-Conserving Surgery, but Disparities Remain
June 17th 2015The number of women deciding to have breast-conserving therapy to treat their early-stage breast cancer has been steadily increasing, but these gains are muted for some women due to such factors as insurance status, income, and travel distance to treatment centers.
Better Treatment Options and Follow-Up Improve Outlook for Childhood Cancer Survivors
June 4th 2015Findings from an analysis of more than 34,000 participants in the Childhood Cancer Survivor Study show that among those who have survived at least 5 years, all-cause mortality at 15 years after diagnosis dropped by half from 12.4% to 6%.
New Trial to Expand Patient Access to Off-Label Use of Targeted Drugs for Many Types of Cancer
June 1st 2015ASCO's first-ever clinical trial aims to match patients who have run out of treatment options with therapies that are FDA-approved to treat tumors with their genetic variant but for a different type of cancer.
Novel Oral Agent Palbociclib Stalls Progression in HR-Positive Breast Cancer
May 31st 2015Adding palbociclib (Ibrance) to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer, according to study results presented at the 2015 ASCO Annual Meeting.
Survey Examines What's Driving Patient Decisions to Use Complementary Therapies
May 28th 2015Complementary and alternative therapies like yoga and acupuncture are becoming more popular among cancer patients and survivors to help ease symptoms like pain, fatigue, and distress, but what drives-and deters-the use of these integrative therapies is not well understood.